Style | Citing Format |
---|---|
MLA | M Golabi MOHAMMADSAID, M Mohammadisichani MARYAM, S Rostami SODABEH. "Prevalence of Erythromycin Resistance Genes in Gram-Positive and Gram-Negative Bacteria From Secondary Infections." Avicenna Journal of Clinical Microbiology and Infection, vol. 12, no. 2, 2025, pp. 61-66. |
APA | M Golabi MOHAMMADSAID, M Mohammadisichani MARYAM, S Rostami SODABEH (2025). Prevalence of Erythromycin Resistance Genes in Gram-Positive and Gram-Negative Bacteria From Secondary Infections. Avicenna Journal of Clinical Microbiology and Infection, 12(2), 61-66. |
Chicago | M Golabi MOHAMMADSAID, M Mohammadisichani MARYAM, S Rostami SODABEH. "Prevalence of Erythromycin Resistance Genes in Gram-Positive and Gram-Negative Bacteria From Secondary Infections." Avicenna Journal of Clinical Microbiology and Infection 12, no. 2 (2025): 61-66. |
Harvard | M Golabi MOHAMMADSAID, M Mohammadisichani MARYAM, S Rostami SODABEH (2025) 'Prevalence of Erythromycin Resistance Genes in Gram-Positive and Gram-Negative Bacteria From Secondary Infections', Avicenna Journal of Clinical Microbiology and Infection, 12(2), pp. 61-66. |
Vancouver | M Golabi MOHAMMADSAID, M Mohammadisichani MARYAM, S Rostami SODABEH. Prevalence of Erythromycin Resistance Genes in Gram-Positive and Gram-Negative Bacteria From Secondary Infections. Avicenna Journal of Clinical Microbiology and Infection. 2025;12(2):61-66. |
BibTex | @article{ author = {M Golabi MOHAMMADSAID and M Mohammadisichani MARYAM and S Rostami SODABEH}, title = {Prevalence of Erythromycin Resistance Genes in Gram-Positive and Gram-Negative Bacteria From Secondary Infections}, journal = {Avicenna Journal of Clinical Microbiology and Infection}, volume = {12}, number = {2}, pages = {61-66}, year = {2025} } |
RIS | TY - JOUR AU - M Golabi MOHAMMADSAID AU - M Mohammadisichani MARYAM AU - S Rostami SODABEH TI - Prevalence of Erythromycin Resistance Genes in Gram-Positive and Gram-Negative Bacteria From Secondary Infections JO - Avicenna Journal of Clinical Microbiology and Infection VL - 12 IS - 2 SP - 61 EP - 66 PY - 2025 ER - |